Literature DB >> 19917308

New horizons for therapeutics in drug and alcohol abuse.

Bianca Jupp1, Andrew J Lawrence.   

Abstract

Alcohol, tobacco and illicit drug dependence represents a serious health and social issue within the community. As drug dependence has become more widely recognized as a clinical disorder and the severity of the problem been fully realized, options available for treatment have grown along with our understanding of the neurobiological mechanisms underlying the development and persistence of addiction. Treatment has progressed from purely social and behavioral approaches to now encompass pharmacotherapy to attempt to disrupt the mechanisms underlying these disorders. Despite these advances, many forms of addiction lack effective therapeutics and the prevalence of this disorder remains unacceptably high. As a result, a significant effort within the research community has been dedicated to the identification of novel targets for the development of therapeutics based upon our understanding of the pathological processes underlying addiction. The current review aims to provide an overview of existing and clinically trialed pharmacotherapies for alcohol, opiate, psychostimulant, nicotine, cannabis and inhalant addictions. Further, we discuss some of the potential targets that have been recently indentified from basic studies that may hold promise for the development of novel treatments.

Entities:  

Mesh:

Year:  2009        PMID: 19917308     DOI: 10.1016/j.pharmthera.2009.11.002

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  27 in total

Review 1.  Cognitive effects of Group I metabotropic glutamate receptor ligands in the context of drug addiction.

Authors:  M Foster Olive
Journal:  Eur J Pharmacol       Date:  2010-04-02       Impact factor: 4.432

2.  Cocaine potentiates excitatory drive in the perifornical/lateral hypothalamus.

Authors:  Jiann Wei Yeoh; Morgan H James; Phillip Jobling; Jaideep S Bains; Brett A Graham; Christopher V Dayas
Journal:  J Physiol       Date:  2012-05-28       Impact factor: 5.182

3.  A randomized clinical trial of naltrexone and behavioral therapy for problem drinking men who have sex with men.

Authors:  Jon Morgenstern; Alexis N Kuerbis; Andrew C Chen; Christopher W Kahler; Donald A Bux; Henry R Kranzler
Journal:  J Consult Clin Psychol       Date:  2012-05-21

Review 4.  Proteomic approaches and identification of novel therapeutic targets for alcoholism.

Authors:  Giorgio Gorini; R Adron Harris; R Dayne Mayfield
Journal:  Neuropsychopharmacology       Date:  2013-07-31       Impact factor: 7.853

Review 5.  Pharmacological and psychosocial management of mental, neurological and substance use disorders in low- and middle-income countries: issues and current strategies.

Authors:  Jair de Jesus Mari; Luís Fernando Tófoli; Cristiano Noto; Li M Li; Alessandra Diehl; Angélica M Claudino; Mario F Juruena
Journal:  Drugs       Date:  2013-09       Impact factor: 9.546

6.  Central amygdala relaxin-3/relaxin family peptide receptor 3 signalling modulates alcohol seeking in rats.

Authors:  Leigh C Walker; Hanna E Kastman; Elena V Krstew; Andrew L Gundlach; Andrew J Lawrence
Journal:  Br J Pharmacol       Date:  2017-08-23       Impact factor: 8.739

Review 7.  Animal models for medications development targeting alcohol abuse using selectively bred rat lines: neurobiological and pharmacological validity.

Authors:  Richard L Bell; Helen J K Sable; Giancarlo Colombo; Petri Hyytia; Zachary A Rodd; Lawrence Lumeng
Journal:  Pharmacol Biochem Behav       Date:  2012-07-25       Impact factor: 3.533

Review 8.  An efficient early phase 2 procedure to screen medications for efficacy in smoking cessation.

Authors:  Kenneth A Perkins; Caryn Lerman
Journal:  Psychopharmacology (Berl)       Date:  2013-12-03       Impact factor: 4.530

9.  Relaxin-3/RXFP3 system regulates alcohol-seeking.

Authors:  Philip J Ryan; Hanna E Kastman; Elena V Krstew; K Johan Rosengren; Mohammed Akhter Hossain; Leonid Churilov; John D Wade; Andrew L Gundlach; Andrew J Lawrence
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-02       Impact factor: 11.205

Review 10.  Chronic methamphetamine self-administration disrupts cortical control of cognition.

Authors:  Aurelien Bernheim; Ronald E See; Carmela M Reichel
Journal:  Neurosci Biobehav Rev       Date:  2016-07-20       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.